Biogen Wins FDA Approval for Subcutaneous Starter Dose of Leqembi

Biogen (BIIB) received FDA approval for Leqembi Iqlik, enabling early Alzheimer’s patients to begin treatment with a weekly at-home autoinjector rather than biweekly IV infusions. The approval is a meaningful execution win that should improve usability/adoption versus clinic-based dosing. Market impact is likely to be stock/sector-moving given the regulatory milestone and potential expansion in the addressable treatment pathway.

Analysis

Biogen (BIIB) received FDA approval for Leqembi Iqlik, enabling early Alzheimer’s patients to begin treatment with a weekly at-home autoinjector rather than biweekly IV infusions. The approval is a meaningful execution win that should improve usability/adoption versus clinic-based dosing. Market impact is likely to be stock/sector-moving given the regulatory milestone and potential expansion in the addressable treatment pathway.